



Janet T. Mills
Governor

STATE OF MAINE
DEPARTMENT OF PROFESSIONAL
AND FINANCIAL REGULATION
OFFICE OF PROFESSIONAL AND OCCUPATIONAL REGULATION
BOARD OF PHARMACY
35 STATE HOUSE STATION
AUGUSTA, MAINE
04333-0035

Anne L. Head, Esq.
Commissioner

Geraldine L. Betts
Administrator

July 27, 2021

To: The Joint Standing Committee on Health and Human Services

Re: ***Pursuant to L.D. 793, An Act To Improve Accountability of Opioid Manufacturers***
Report on Implementation of Public Law 2020 Chapter 536 and Fees Collected From
Opioid Medication and Product Registration

Dear Senator Claxton, Representative Meyer, and Members of the Joint Standing Committee on Health and Human Services:

During the 129th Maine Legislature, President Jackson presented L.D. 793, “An Act To Improve Accountability of Opioid Manufacturers.” The bill was enacted as [Public Law 2020, Chapter 536](#) on January 12, 2020, effective on June 16, 2020. The bill established an Opioid Use Disorder Prevention and Treatment Fund, to be used for opioid use disorder prevention and treatment services administered by the Department of Health and Human Services. The law provides that the Fund would be financed by fee assessments collected by the Board of Pharmacy from opioid manufacturers. The following is a summary of the Maine Board of Pharmacy’s experience with implementation of this law, followed by the Board’s report pursuant to Section 4 of L.D. 793¹.

Updates to Agency Licensing Management System

One of the first steps in implementing this new law was to update ALMS² computer configurations to create an intake category for opioid manufacturers and to allow for collection of the fee assessments. The law requires a manufacturer of an opioid medication to pay an annual \$55,000 fee, and any manufacturer that sells, delivers or distributes two million or more units of opioid medication in Maine to pay an annual registration fee of \$250,000. Manufacturers that sell, deliver or distribute two million or less units of an opioid medication in the state in a year are exempt from the \$250,000 fee.

The higher than usual fee assessments presented a situation in which the ALMS software was not capable of collecting and processing the fee payments, if made by credit card, without the Board incurring very high service charges (upwards of \$7,500 for *each* transaction). This presented a transaction cost that the Board of Pharmacy could not absorb.

¹ The Board acknowledges this report to the Joint Standing Committee on Health and Human Services was due March 1, 2021, and we sincerely apologize for the delay. The contents of this memorandum and report more fully explain the factors contributing to the delay.

² “ALMS” stands for Agency Licensing Management System, and is the database used by all of the boards, commissions and regulatory functions of the Office of Professional and Occupational Regulation, to process and track license applications, renewals, and fee payments.

As a result, Board staff worked with individuals in the State Treasury, the Office of Professional and Occupational Regulations accounting division and the ALMS licensing system group to find a resolution to the problem. This process took several months. Thanks to everyone’s combined efforts, a separate accounting system, called ACH, now allows our Office to collect large fee amounts without incurring credit card service charges.

All related ALMS reconfigurations were completed in October 2020.

Opioid Medications Excluded from Calculation of Two Million Units Sold, Delivered or Distributed

When calculating the units of an opioid medication to determine whether to assess the product registration fee, the law provides certain opioid medication used for the purpose of medication-assisted treatment (MAT) of substance use disorder be excluded. The law provides that the Board shall periodically provide to DHHS a list of medications exempted. The following is a current list of medication-assisted treatment for substance use disorders that are excluded from the 2 million unit calculation:

Table 1. Medications Exempted from Units of Opioid Medication Calculation

FDA-approved buprenorphine products approved for the treatment of opioid dependence	Bunavail (buprenorphine and naloxone) buccal film
	Cassipa (buprenorphine and naloxone) sublingual film
	Probuphine (buprenorphine) implant for subdermal administration
	Sublocade (buprenorphine extended-release) injection for subcutaneous use
	Suboxone (buprenorphine and naloxone) sublingual film for sublingual or buccal use, or sublingual tablet
	Subutex (buprenorphine) sublingual tablet
	Zubsolv (buprenorphine and naloxone) sublingual tablets
FDA-approved methadone products approved for the treatment of opioid dependence	Dolophine (methadone hydrochloride) tablets
	Methadose (methadone hydrochloride) oral concentrate
	Levo-alpha-acetylmethadol (LAAM or Orlaam)
FDA-approved naltrexone products approved for the treatment of opioid dependence	Vivitrol (naltrexone for extended-release injectable suspension intramuscular)

Notice to Maine-Licensed Manufacturers and Evaluation of Exception Requests

On October 6, 2020, notice was sent to all Maine-licensed manufacturers regarding the new opioid fee assessments. The notice provided information regarding the Board of Pharmacy’s responsibility to collect the assessment and product registration fee(s) from a manufacturer whose opioid medication product is sold, delivered, or distributed within Maine. *See the [Notice to Licensed Manufacturers, October 6, 2020](#)*. In response, many questions were raised by manufacturers, including questions and requests for additional guidance as to exception requests pursuant to 32 M.R.S. § 13800-C, subsection 2.

The Board responded on May 12, 2021, with a guidance document titled [Registration Fee and Report 2020 Opiate Distributions for Exception Requests](#), which was distributed to all licensed manufacturers. Any manufacturer seeking relief from the \$250,000 product registration fee

because it purportedly did not sell, deliver, or distribute 2,000,000 or more units of an opioid medication in Maine, was directed to submit to the Board data regarding the manufacturer's distributions of DEA Schedules II-IV (opiates only) by May 26, 2021.

It was discovered during a recent contact with representatives for the Department of Health and Human Services, Prescription Monitoring Program (PMP), that Automation of Reports and Consolidated Orders System (ARCOS) reports³ would greatly assist the Board when considering an exception request from a manufacturer by providing a system of checks and balances. Using these reports will enable verification as to whether the number of opioid drugs sold, delivered, or distributed in Maine by a particular manufacturer met or exceeded 2,000,000 million units.

The representatives from the PMP agreed to share the ARCOS reports received from manufacturers and wholesalers upon receipt. Because the sharing of these reports has just started, it will take some time for the information to be used by the Board when considering a request from a manufacturer for an exception. Over the coming months, the Board will begin its review and consideration of exception requests from the product registration requirement.

Effect of Fees on Prescribing Practices of Opioid Medications

Additional time is needed to evaluate whether the fee assessment and product registration fee have in any way affected or reduced opioid medication prescribing habits. Currently the Board does not have the means to assess or make a determination on the prescribing impact, if any, other than to observe that no complaints have been received claiming that Maine citizens have been unable to obtain opioid medication that was prescribed to them, or that a pharmacist was unable to obtain an opioid prescription medication to dispense upon presentation of a valid prescription drug order.

Conclusion

Attached you will find a summary of the manufacturer fee assessments and product registration fees collected from October 6, 2020, through June 7, 2021, together with a listing of the manufacturers and their contact information.

Implementing this new law has required a significant undertaking by Board staff, in part due to the unexpected difficulty with making adjustments to the ALMS software, combined with the general challenges that have been caused by the pandemic. We appreciate your patience and understanding and will strive for the next reports to be provided in accordance with the law's schedule.

To that end, the next reports to the Joint Standing Committee on Health and Human Services will be due on March 1, 2022, and March 1, 2023. The law is scheduled for repeal on September 1, 2023.

End

³ Public Law Chapter 536 requires manufacturers and wholesalers to provide the PMP with a copy of the report on ARCOS on opioids for Maine filed with the United States Drug Enforcement Administration.

Opioid Use Disorder Prevention and Treatment Fund
[Public Law 2020 Chapter 536 \(LD 793\) Effective June 16, 2020](#)
Report on Manufacturer Fee Assessments and Product Registration Fees Collected
October 2020 through June 7, 2021

Board of Pharmacy collects a \$55,000 fee assessment from each opioid medication manufacturer, and \$250,000 product registration fee for manufacturers that sell, delivery or distribute 2,000,000 or more units of an opioid medication with Maine. Fees do not apply to a manufacturer of an opioid medication if all of that manufacturer's opioid medications are approved by the United States Food and Drug Administration for use only in veterinary medicine. Certain opioid medication units are excluded from the calculation of the 2,000,000 units, if prescribed for the purpose of medication-assisted treatment of substance use disorder.

Notices sent to all Maine-licensed Manufacturers, and posted to the Board of Pharmacy webpage

- Initial notice to Licensed Manufacturers Opening Date for Online Registration: October 6, 2020
- Registration Fee and Report 2020 Opiate Distributions for Exception Requests and FAQs: May 12, 2021

Number of MFO

- A total of 23 manufacturers reported to the Board that they manufacture opioids.
- A total of 3 manufacturers reported to the Board that they manufacture opioids that are FDA-approved for veterinary use only, and are therefore not subject to the fee assessment.
- Only 1 manufacturer reported to the Board that it sold, delivered or distributed 2 million or more opioid medication unites in Maine in the preceding year (2020).

Fees collected October 7, 2020 through June 7, 2021

➤ \$55,000 Fee assessments	\$1,925,000
➤ \$250,000 Product registration fees (collected from one manufacturer)	\$ 250,000
➤ \$325 fee retain by the Board of Pharmacy as provided for under Title 5, § 20010, Section 1(B) for administration and collection and transfer fees to the Fund	(\$ 11,375)
<i>Total amount transferred to the Opioid Treatment Fund:</i>	\$2,163,625

Licensure Renewal: Manufacturer (MFO) licenses expire December 31, 2021, and are subject to another round of fee assessments. Throughout the year, new manufacturers (initial licensure) will apply for licensure and are subject to the \$55,000 fee assessment upon initial application for licensure. At the time of renewal, an MFO that responds to having manufactured 2 million or more opioids will also be subject to the \$250,000 product registration fee.

Maine Office of Professional and Occupational Regulation
Board of Pharmacy
Report Date: June 7, 2021

End

STATE OF MAINE - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION
OFFICE OF PROFESSIONAL AND OCCUPATIONAL REGULATION - MAINE BOARD OF PHARMACY

Selection File: MFO

MFO30001883 - AMERISOURCE HEALTH SERVICES LLCDesig. Phys: 2550 JOHN GLENN AVE STE A
COLUMBUS, OH 43217-1188
(FRANKLIN)

Desig. Phone: +1 (614) 492-8177

Desig. Mail: 2550 JOHN GLENN AVE STE A
COLUMBUS, OH 43217-1188
(FRANKLIN)

Desig. Fax:

MFO30001884 - AMNEAL PHARMACEUTICALS OF NEW YORK LLCDesig. Phys: 50 HORSEBLOCK RD
BROOKHAVEN, NY 11719-9509
(SUFFOLK)

Desig. Phone: +1 (908) 381-2076

Desig. Mail: 400 CROSSING BLVD FL 3
BRIDGEWATER, NJ 08807-2863
(SOMERSET)

Desig. Fax:

MFO30001885 - AMNEAL PHARMACEUTICALS OF NEW YORK, LLCDesig. Phys: 75 ADAMS AVE
HAUPPAUGE, NY 11788-3605
(SUFFOLK)

Desig. Phone: +1 (631) 952-0214

Desig. Mail: 400 CROSSING BLVD FL 3
BRIDGEWATER, NJ 08807-2863
(SOMERSET)

Desig. Fax: +1 (631) 656-2505

MFO30001921 - ANESTA LLCDesig. Phys: 4745 W WILEY POST WAY
SALT LAKE CITY, UT 84116-2884 (SALT
LAKE)

Desig. Phone: +1 (801) 525-1405

Desig. Mail: C/O KELLY ODOGNOGUE
1090 HORSHAM RD
NORTH WALES, PA 19454-1505
(MONTGOMERY)

Desig. Fax: +1 (801) 595-1406

MFO30001867 - ATLAS PHARMACEUTICALS LLCDesig. Phys: 711 E CAREFREE HWY STE 107
PHOENIX, AZ 85085-0103 (MARICOPA)

Desig. Phone: +1 (844) 661-1829

Desig. Mail: 711 E CAREFREE HWY STE 207
PHOENIX, AZ 85085-0109 (MARICOPA)

Desig. Fax: +1 (623) 582-7970

MFO30001887 - ELANCO US INCDesig. Phys: 12707 SHAWNEE MISSION PKWY
SHAWNEE MISSION, KS 66216-1846
(JOHNSON)

Desig. Phone: +1 (317) 220-2913

Desig. Mail: 12707 SHAWNEE MISSION PKWY
SHAWNEE MISSION, KS 66216-1846
(JOHNSON)

Desig. Fax:

MFO30001856 - FRESENIUS KABI USA LLCDesig. Phys: 5200 CORPORATE PKWY
WILSON, NC 27893-9412 (WILSON)

Desig. Phone: +1 (614) 553-3076

Desig. Mail: ATTN QRA - FACILITY LICENSING
7000 CARDINAL PL
DUBLIN, OH 43017-1091 (FRANKLIN)

Desig. Fax: +1 (614) 652-0674

MFO30001857 - FRESENIUS KABI USA LLC

STATE OF MAINE - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION
OFFICE OF PROFESSIONAL AND OCCUPATIONAL REGULATION - MAINE BOARD OF PHARMACY

Desig. Phys: 3159 STALEY RD
GRAND ISLAND, NY 14072-2028 (ERIE)

Desig. Phone: +1 (614) 553-3076

Desig. Mail: ATTN QRA - FACILITY LICENSING
7000 CARDINAL PL
DUBLIN, OH 43017-1091 (FRANKLIN)

Desig. Fax: +1 (614) 652-0674

MFO30001886 - GOLDEN STATE MEDICAL SUPPLY INC

Desig. Phys: 5187 CAMINO RUIZ
CAMARILLO, CA 93012-8601
(VENTURA)

Desig. Phone: +1 (805) 477-9866

Desig. Mail: 5187 CAMINO RUIZ
CAMARILLO, CA 93012-8601
(VENTURA)

Desig. Fax: +1 (805) 437-7582

MFO30001860 - HIKMA PHARMACEUTICALS USA INC

Desig. Phys: 1809 WILSON RD
COLUMBUS, OH 43228-9579
(FRANKLIN)

Desig. Phone: +1 (614) 276-4000

Desig. Mail: 1809 WILSON RD
COLUMBUS, OH 43228-9579
(FRANKLIN)

Desig. Fax: +1 (614) 274-0974

MFO30001865 - HOSPIRA INC

Desig. Phys: HIGHWAY 301 NORTH
ROCKY MOUNT, NC

Desig. Phone: +1 (252) 977-5710

Desig. Mail: 1855 SHELBY OAKS DR N
MEMPHIS, TN 38134-7444 (SHELBY)

Desig. Fax:

MFO30001866 - HOSPIRA INC

Desig. Phys: 1776 CENTENNIAL DR
MCPHERSON, KS 67460-9301
(MCPHERSON)

Desig. Phone: +1 (901) 275-0040

Desig. Mail: 1855 SHELBY OAKS DR N
MEMPHIS, TN 38134-7444 (SHELBY)

Desig. Fax:

MFO30001863 - KINDEVA DRUG DELIVERY LP

Desig. Phys: 19901 NORDHOFF ST
NORTHRIDGE, CA 91324-3213 (LOS
ANGELES)

Desig. Phone: +1 (818) 341-1300

Desig. Mail: 19901 NORDHOFF ST
NORTHRIDGE, CA 91324-3213 (LOS
ANGELES)

Desig. Fax: +1 (818) 709-3055

MFO30001888 - KREMERS URBAN PHARMACEUTICALS INC

Desig. Phys: 1101 C AVE W
SEYMOUR, IN 47274-3342 (JACKSON)

Desig. Phone: +1 (812) 523-3457

Desig. Mail: 1101 C AVE W
SEYMOUR, IN 47274-3342 (JACKSON)

Desig. Fax: +1 (812) 523-1887

MFO30001895 - MAYNE PHARMA INC

Desig. Phys: 1240 SUGG PKWY
GREENVILLE, NC 27834-9006 (PITT)

Desig. Phone: +1 (252) 752-3800

Desig. Mail: C/O STATE LICENSE SERVICING
1751 STATE ROUTE 17A STE 3
FLORIDA, NY 10921-1061 (ORANGE)

Desig. Fax: +1 (252) 758-8522

STATE OF MAINE - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION
OFFICE OF PROFESSIONAL AND OCCUPATIONAL REGULATION - MAINE BOARD OF PHARMACY

MFO30001861 - MYLAN PHARMACEUTICALS INC

Desig. Phys: 781 CHESTNUT RIDGE RD
MORGANTOWN, WV 26505-2730
(MONONGALIA)

Desig. Phone: +1 (304) 599-2595

Desig. Mail: PO BOX 4310
781 CHESTNUT RIDGE RD
MORGANTOWN, WV 26505-2730
(MONONGALIA)

Desig. Fax:

MFO30001893 - NORWICH PHARMACEUTICALS INC

Desig. Phys: 6826 STATE HIGHWAY 12
NORWICH, NY 13815-3335
(CHENANGO)

Desig. Phone: +1 (607) 335-3000

Desig. Mail: 6826 STATE HIGHWAY 12
NORWICH, NY 13815-3335
(CHENANGO)

Desig. Fax:

MFO30001899 - NOVEL LABORATORIES INC

Desig. Phys: 400 CAMPUS DR
SOMERSET, NJ 08873-1145
(SOMERSET)

Desig. Phone: +1 (908) 603-6000

Desig. Mail: 400 CAMPUS DR
SOMERSET, NJ 08873-1145
(SOMERSET)

Desig. Fax:

MFO30001891 - PADDOCK LABORATORIES LLC

Desig. Phys: 3940 QUEBEC AVE N
MINNEAPOLIS, MN 55427-1244
(HENNEPIN)

Desig. Phone: +1 (763) 546-4676

Desig. Mail: 1025 BOULDERS PKWY STE 301
NORTH CHESTERFIELD, VA 23225-5549
(CHESTERFIELD)

Desig. Fax:

MFO30001854 - PAR PHARMACEUTICAL INC

Desig. Phys: 1 RAM RIDGE RD
CHESTNUT RIDGE, NY 10977-6714
(ROCKLAND)

Desig. Phone: +1 (800) 927-5727

Desig. Mail: 1 RAM RIDGE RD
CHESTNUT RIDGE, NY 10977-6714
(ROCKLAND)

Desig. Fax: +1 (845) 425-8956

MFO30001855 - PURDUE PHARMACEUTICALS L P

Desig. Phys: VP MFG/SUPPLY CHN
4701 PURDUE DR W
WILSON, NC 27893-9680 (WILSON)

Desig. Phone: +1 (252) 265-1900

Desig. Mail: ATTN DONOGH MCGUIRE VP
OPERATIONS
4701 PURDUE DR W
WILSON, NC 27893-9680 (WILSON)

Desig. Fax:

MFO30001862 - QUVA PHARMA INC

Desig. Phys: 1075 W PARK ONE DR
SUGAR LAND, TX 77478-2576 (FORT
BEND)

Desig. Phone: +1 (888) 339-0874

Desig. Mail: 1075 W PARK ONE DR
SUGAR LAND, TX 77478-2576 (FORT
BEND)

Desig. Fax:

STATE OF MAINE - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION
OFFICE OF PROFESSIONAL AND OCCUPATIONAL REGULATION - MAINE BOARD OF PHARMACY

MFO30001912 - QUVA PHARMA INC

Desig. Phys: 519 STATE ROUTE 173
BLOOMSBURY, NJ 08804-4047
(WARREN)
Desig. Phone: +1 (888) 339-0874

Desig. Mail: 519 STATE ROUTE 173
BLOOMSBURY, NJ 08804-4047
(WARREN)
Desig. Fax:

MFO30001874 - TRIS PHARMA INC

Desig. Phys: 2033 ROUTE 130
MONMOUTH JUNCTION, NJ
Desig. Phone: +1 (732) 940-2800

Desig. Mail: 2033 ROUTE 130
MONMOUTH JUNCTION, NJ
Desig. Fax: +1 (732) 940-2855

MFO30001859 - UPSHER-SMITH LABORATORIES LLC

Desig. Phys: 14905 23RD AVE N
PLYMOUTH, MN 55447-4708
(HENNEPIN)
Desig. Phone: +1 (763) 315-2000

Desig. Mail: 6701 EVENSTAD DR N
MAPLE GROVE, MN 55369-6026
(HENNEPIN)
Desig. Fax: +1 (763) 258-5578

MFO30001919 - WEDGEWOOD CONNECT LLC

Desig. Phys: 17 GREAT OAKS BLVD
SAN JOSE, CA 95119-1359 (SANTA
CLARA)
Desig. Phone: +1 (800) 216-5005

Desig. Mail: 17 GREAT OAKS BLVD
SAN JOSE, CA 95119-1359 (SANTA
CLARA)
Desig. Fax:

LastName	LicensePrefix	LicenseNumber	Fee Assesses	IssueDate	Expiration	FirstLicenseDate	Mailing Address	Address2	Address4	Address5	City	State	ZipCode	County	Country	Authority1	Physical Address	Physical Address	Physical Address	Homecity	Home_state	Home_zip	Home_county
AMERISOURCE HEALTH SERVICES LLC	MFO	30001883	\$55,000 Original MFO	4-Jan-21	31-Dec-21	4-Jan-21	2550 JOHN GLENN AVE STE A			COLUMBUS, OH 43217-1188	COLUMBUS	OH	43217-1188	FRANKLIN		Human Opioid Manufacturing	2550 JOHN GLENN AVE STE A		COLUMBUS, OH 43217-1188	COLUMBUS	OH	43217-1188	FRANKLIN
AMNEAL PHARMACEUTICALS OF NEW YORK LLC	MFO	30001884	\$55,000 Original MFO	7-Jan-21	31-Dec-21	7-Jan-21	400 CROSSING BLVD FL 3			BRIDGEWATER, NJ 08807-2863	BRIDGEWATER	NJ	08807-2863	SOMERSET		Human Opioid Manufacturing	50 HORSEBLOCK RD		BROOKHAVEN, NY 11719-9509	BROOKHAVEN	NY	11719-9509	SUFFOLK
AMNEAL PHARMACEUTICALS OF NEW YORK, LLC	MFO	30001885	\$55,000 Original MFO	7-Jan-21	31-Dec-21	7-Jan-21	400 CROSSING BLVD FL 3			BRIDGEWATER, NJ 08807-2863	BRIDGEWATER	NJ	08807-2863	SOMERSET		Human Opioid Manufacturing	75 ADAMS AVE		HAUPPAUGE, NY 11788-3605	HAUPPAUGE	NY	11788-3605	SUFFOLK
ANESTA LLC	MFO	30001921	\$55,000 Original MFO	24-May-21	31-Dec-21	24-May-21	C/O KELLY ODONOGHUE	1090 HORSHAM RD		NORTH WALES, PA 19454-1505	NORTH WALES	PA	19454-1505	MONTGOMERY		Human Opioid Manufacturing	4745 W WILEY POST WAY		SALT LAKE CITY, UT 84116-2884	SALT LAKE CITY	UT	84116-2884	SALT LAKE
ATLAS PHARMACEUTICALS LLC	MFO	30001867	0 Vet Only	2-Dec-20	31-Dec-21	1-Dec-20	711 E CAREFREE HWY STE 207			PHOENIX, AZ 85085-0109	PHOENIX	AZ	85085-0109	MARICOPA		Opioids FDA-approved for Veterinary-use ONLY	711 E CAREFREE HWY STE 107		PHOENIX, AZ 85085-0103	PHOENIX	AZ	85085-0103	MARICOPA
ELANCO US INC	MFO	30001887	0 Vet Only	26-Jan-21	31-Dec-21	26-Jan-21	12707 SHAWNEE MISSION PKWY			SHAWNEE MISSION, KS 66216-1846	SHAWNEE MISSION	KS	66216-1846	JOHNSON		Opioids FDA-approved for Veterinary-use ONLY	12707 SHAWNEE MISSION PKWY		SHAWNEE MISSION, KS 66216-1846	SHAWNEE MISSION	KS	66216-1846	JOHNSON
FRESENIUS KABI USA LLC	MFO	30001856	\$55,000 Original MFO and at Renewal \$55,000	11-Dec-20	31-Dec-21	19-Oct-20	ATTN QRA - FACILITY LICENSING	7000 CARDINAL PL		DUBLIN, OH 43017-1091	DUBLIN	OH	43017-1091	FRANKLIN		Human Opioid Manufacturing	5200 CORPORATE PKWY		WILSON, NC 27893-9412	WILSON	NC	27893-9412	WILSON
FRESENIUS KABI USA LLC	MFO	30001857	\$55,000 Original MFO and at Renewal \$55,000	11-Dec-20	31-Dec-21	19-Oct-20	ATTN QRA - FACILITY LICENSING	7000 CARDINAL PL		DUBLIN, OH 43017-1091	DUBLIN	OH	43017-1091	FRANKLIN		Human Opioid Manufacturing	3159 STALEY RD		GRAND ISLAND, NY 14072-2028	GRAND ISLAND	NY	14072-2028	ERIE
GOLDEN STATE MEDICAL SUPPLY INC	MFO	30001886	\$55,000 Original MFO	16-Nov-20	31-Dec-21	16-Nov-20	5187 CAMINO RUIZ			CAMARILLO, CA 93012-8601	CAMARILLO	CA	93012-8601	VENTURA		Human Opioid Manufacturing	5187 CAMINO RUIZ		CAMARILLO, CA 93012-8601	CAMARILLO	CA	93012-8601	VENTURA
HIKMA PHARMACEUTICALS USA INC	MFO	30001860	\$55,000 Original MFO and at Renewal \$55,000	15-Dec-20	31-Dec-21	19-Oct-20	1809 WILSON RD			COLUMBUS, OH 43228-9579	COLUMBUS	OH	43228-9579	FRANKLIN		Human Opioid Manufacturing	1809 WILSON RD		COLUMBUS, OH 43228-9579	COLUMBUS	OH	43228-9579	FRANKLIN
HOSPIRA INC	MFO	30001865	\$55,000 Original MFO and at Renewal \$55,000	10-Dec-20	31-Dec-21	19-Oct-20	1855 SHELBY OAKS DR N			MEMPHIS, TN 38134-7444	MEMPHIS	TN	38134-7444	SHELBY		Human Opioid Manufacturing	HIGHWAY 301 NORTH		ROCKY MOUNT, NC	ROCKY MOUNT	NC		
HOSPIRA INC	MFO	30001866	\$55,000 Original MFO and at Renewal \$55,000	10-Dec-20	31-Dec-21	30-Oct-20	1855 SHELBY OAKS DR N			MEMPHIS, TN 38134-7444	MEMPHIS	TN	38134-7444	SHELBY		Human Opioid Manufacturing	1776 CENTENNIAL DR		MCPHERSON, KS 67460-9301	MCPHERSON	KS	67460-9301	MCPHERSON
KINDEVA DRUG DELIVERY LP	MFO	30001863	\$55,000 Original MFO and at Renewal \$55,000	1-Jan-21	31-Dec-21	30-Oct-20	19901 NORDHOFF ST			NORTHRIDGE, CA 91324-3213	NORTHRIDGE	CA	91324-3213	LOS ANGELES		Human Opioid Manufacturing	19901 NORDHOFF ST		NORTHRIDGE, CA 91324-3213	NORTHRIDGE	CA	91324-3213	LOS ANGELES
KREMERS URBAN PHARMACEUTICALS INC	MFO	30001888	\$55,000 Original MFO	28-Jan-21	31-Dec-21	28-Jan-21	1101 C AVE W			SEYMOUR, IN 47274-3342	SEYMOUR	IN	47274-3342	JACKSON		Human Opioid Manufacturing	1101 C AVE W		SEYMOUR, IN 47274-3342	SEYMOUR	IN	47274-3342	JACKSON
MAYNE PHARMA INC	MFO	30001895	\$55,000 Original MFO and at Renewal \$55,000	4-Mar-21	31-Dec-21	4-Mar-21	C/O STATE LICENSE SERVICING	1751 STATE ROUTE 17A STE 3		FLORIDA, NY 10921-1061	FLORIDA	NY	10921-1061	ORANGE		Human Opioid Manufacturing	1240 SUGG PKWY		GREENVILLE, NC 27834-9006	GREENVILLE	NC	27834-9006	PITT
MYLAN PHARMACEUTICALS INC	MFO	30001861	\$55,000 Original MFO and at Renewal \$55,000	8-Jan-21	31-Dec-21	30-Oct-20	PO BOX 4310	781 CHESTNUT RIDGE RD		MORGANTOWN, WV 26505-2730	MORGANTOWN	WV	26505-2730	MONONGALIA		Human Opioid Manufacturing	781 CHESTNUT RIDGE RD		MORGANTOWN, WV 26505-2730	MORGANTOWN	WV	26505-2730	MONONGALIA
NORWICH PHARMACEUTICALS INC	MFO	30001893	\$55,000 Original MFO	9-Feb-21	31-Dec-21	9-Feb-21	6826 STATE HIGHWAY 12			NORWICH, NY 13815-3335	NORWICH	NY	13815-3335	CHENANGO		Human Opioid Manufacturing	6826 STATE HIGHWAY 12		NORWICH, NY 13815-3335	NORWICH	NY	13815-3335	CHENANGO
NOVEL LABORATORIES INC	MFO	30001899	\$55,000 Original MFO	11-Mar-21	31-Dec-21	11-Mar-21	400 CAMPUS DR			SOMERSET, NJ 08873-1145	SOMERSET	NJ	08873-1145	SOMERSET		Human Opioid Manufacturing	400 CAMPUS DR		SOMERSET, NJ 08873-1145	SOMERSET	NJ	08873-1145	SOMERSET
PADDOCK LABORATORIES LLC	MFO	30001891	\$55,000 Original MFO	4-Feb-21	31-Dec-21	4-Feb-21	1025 BOULDERS PKWY STE 301			NORTH CHESTERFIELD, VA 23225-5549	NORTH CHESTERFIELD	VA	23225-5549	CHESTERFIELD		Human Opioid Manufacturing	3940 QUEBEC AVE N		MINNEAPOLIS, MN 55427-1244	MINNEAPOLIS	MN	55427-1244	HENNEPIN
PAR PHARMACEUTICAL INC	MFO	30001854	\$55,000 Original MFO and at Renewal \$55,000	17-Dec-20	31-Dec-21	26-Oct-20	1 RAM RIDGE RD			CHESTNUT RIDGE, NY 10977-6714	CHESTNUT RIDGE	NY	10977-6714	ROCKLAND		Human Opioid Manufacturing	1 RAM RIDGE RD		CHESTNUT RIDGE, NY 10977-6714	CHESTNUT RIDGE	NY	10977-6714	ROCKLAND
PURDUE PHARMACEUTICALS L P	MFO	30001855	\$55,000 Original MFO and at Renewal \$250,000	30-Dec-20	31-Dec-21	23-Oct-20	ATTN DONOGH MCGUIRE VP OPERATIONS	4701 PURDUE DR W		WILSON, NC 27893-9680	WILSON	NC	27893-9680	WILSON		Human Opioid Manufacturing	VP MFG/SUPPLY CHN	4701 PURDUE DR W	WILSON, NC 27893-9680	WILSON	NC	27893-9680	WILSON
QUVA PHARMA INC	MFO	30001862	\$55,000 Original MFO and at Renewal \$55,000	1-Jan-21	31-Dec-21	28-Oct-20	1075 W PARK ONE DR			SUGAR LAND, TX 77478-2576	SUGAR LAND	TX	77478-2576	FORT BEND		Human Opioid Manufacturing	1075 W PARK ONE DR		SUGAR LAND, TX 77478-2576	SUGAR LAND	TX	77478-2576	FORT BEND
QUVA PHARMA INC	MFO	30001912	\$55,000 Original MFO	20-Apr-21	31-Dec-21	20-Apr-21	519 STATE ROUTE 173			BLOOMSBURY, NJ 08804-4047	BLOOMSBURY	NJ	08804-4047	WARREN		Human Opioid Manufacturing	519 STATE ROUTE 173		BLOOMSBURY, NJ 08804-4047	BLOOMSBURY	NJ	08804-4047	WARREN
TRIS PHARMA INC	MFO	30001874	\$55,000 Original MFO and at Renewal \$55,000	26-Jan-21	31-Dec-21	15-Dec-20	2033 ROUTE 130			MONMOUTH JUNCTION, NJ	MONMOUTH JUNCTION	NJ				Human Opioid Manufacturing	2033 ROUTE 130		MONMOUTH JUNCTION, NJ	MONMOUTH JUNCTION	NJ		
UPSHER-SMITH LABORATORIES LLC	MFO	30001859	\$55,000 Original MFO and at Renewal \$55,000	21-Dec-20	31-Dec-21	29-Oct-20	6701 EVENSTAD DR N			MAPLE GROVE, MN 55369-6026	MAPLE GROVE	MN	55369-6026	HENNEPIN		Human Opioid Manufacturing	14905 23RD AVE N		PLYMOUTH, MN 55447-4708	PLYMOUTH	MN	55447-4708	HENNEPIN
WEDGEWOOD CONNECT LLC	MFO	30001919	0 Vet only	18-May-21	31-Dec-21	18-May-21	17 GREAT OAKS BLVD			SAN JOSE, CA 95119-1359	SAN JOSE	CA	95119-1359	SANTA CLARA		Veterinary-use ONLY	17 GREAT OAKS BLVD		SAN JOSE, CA 95119-1359	SAN JOSE	CA	95119-1359	SANTA CLARA